

Luke Hughes-Davies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3687933/publications.pdf>

Version: 2024-02-01

12
papers

539
citations

1307594

7
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

1199
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet, The</i> , 2019, 393, 2599-2612. | 13.7 | 225 |
| 2 | Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2x2 factorial randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 201-212. | 10.7 | 106 |
| 3 | PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 506-506. | 1.6 | 59 |
| 4 | OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-202. | 2.8 | 53 |
| 5 | Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. <i>Value in Health</i> , 2017, 20, 1311-1318. | 0.3 | 31 |
| 6 | Trastuzumab-associated cardiac events in the Persephone trial. <i>British Journal of Cancer</i> , 2016, 115, 1462-1470. | 6.4 | 23 |
| 7 | Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. <i>Modern Pathology</i> , 2017, 30, 1069-1077. | 5.5 | 15 |
| 8 | Six versus 12 monthsâ€™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-190. | 2.8 | 11 |
| 9 | PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS591-TPS591. | 1.6 | 7 |
| 10 | Aiming for a holistic integrated service for men diagnosed with prostate cancer â€“ Definitions of standards and skill sets for nurses and allied healthcare professionals. <i>European Journal of Oncology Nursing</i> , 2017, 29, 31-38. | 2.1 | 4 |
| 11 | Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1014-1014. | 1.6 | 3 |
| 12 | Neo-tAnGo science: A translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1015-1015. | 1.6 | 2 |